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Abstract
Aging involves a progressive physiological remodeling that is controlled by both genetic and environmental factors. Many
of these factors impact also on white adipose tissue (WAT), which has been shown to be a determinant of lifespan.
Interrogating a transcriptional network for predicted causal regulatory interactions in a collection of mouse WAT from F2
crosses with a seed set of 60 known longevity genes, we identified a novel transcriptional subnetwork of 742 genes which
represent thus-far-unknown longevity genes. Within this subnetwork, one gene was Pparg (Nr1c3), an adipose-enriched
nuclear receptor previously not associated with longevity. In silico, both the PPAR signaling pathway and the transcriptional
signature of Pparc agonist rosiglitazone overlapped with the longevity subnetwork, while in vivo, lowered expression of
Pparg reduced lifespan in both the lipodystrophic Pparg1/2-hypomorphic and the Pparg2-deficient mice. These results
establish Pparc2 as one of the determinants of longevity and suggest that lifespan may be rather determined by a
purposeful genetic program than a random process.
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Introduction
Aging is not a disease, but a natural evolution characterized by
declining biological function, whose timeline is sensitive to both
environmental and genetic factors. Several longevity candidate
genes have been identified, including the insulin/IGF1 signaling
pathway [1–3]. With the use of dietary regimens, such as caloric
restriction (CR) and by modulating core body temperature, the
control of energy metabolism has been implicated as a critical
determinant of the aging phenotype [4–6]. A central physiological
component of energy metabolism, involved in energy preservation,
is the white adipose tissue (WAT), which has also been directly
associated with the determination of lifespan [7,8]. However, it is
still uncertain whether WAT modulates aging via its ability to e.g.
store fat, sensitize towards insulin, or produce adipocyte
hormones. Also unknown is the nature of the involved genetic
players and importantly, whether they function in a purposeful
program or as random genetic events.
Using a systems approach we identified a novel subnetwork of
genes in mouse WAT, which potentially impacts longevity,
suggesting that aging is the result of a determined transcriptional
network program and not entirely accidental. Furthermore, the
most significantly enriched biological pathway revealed within this
aging subnetwork was the PPAR signaling pathway. The aging
subnetwork also contained the nuclear receptor Pparg (Nr1c3), a
transcription factor well associated with adipocyte biology [9,10],
but whose contribution to longevity has not been previously
assessed. In this study, we support our network theory of aging by
demonstrating a significantly altered lifespan in 2 independent
genetic mouse models expressing reduced levels of Pparg. Thus, in
addition to providing novel candidate ‘longevity genes’ such as
Pparg2, this study also provides further insight into the potential
role of WAT biology and genetics as determinants of lifespan.
Results/Discussion
We hypothesized that the age-dependent physiological remod-
eling that leads to phenotypic aging is caused by concerted
changes in a longevity-determining genetic network rather than by
random changes at the level of individual genes. This hypothesis
was tested using a mouse transcriptional network that consists of a
union of 4 individual Bayesian networks of predicted causal
regulatory interactions in the WAT generated from individual F2
crosses. We interrogated this network of 13088 genes with a seed
set of 60 genes, derived from public resources, which either
increase or reduce lifespan when genetically perturbed in the
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were also present within the adipose tissue network (Table S1;
Figure 1A). The pair-wise shortest path analysis against 10
6
randomly selected sets of 33 genes showed that these 33 genes on
average were much more tightly connected than expected by
chance (p=0.00149) (Figure 1B). Furthermore, the distribution of
the shortest paths within the set of 33 ‘known’ longevity genes was
significantly tighter than that for the randomly selected sets as
.99% of all Kolmogorov-Smirnov two-sided test p-values were
less than 0.05. This tight, non-random interconnection of known
aging-linked genes suggests that the associated biological phenom-
ena are deliberate such that other ‘unknown’ age-related genes
and/or biological processes may be predicted. This network
theory is reminiscent of the transcriptional consequences of single
genetic perturbations, such as knock-out mouse models or DNA
polymorphisms, which result in concentrations of transcriptional
changes in the genes functionally relating to the perturbed gene
rather than altering genes diffusely distributed across the whole
network [11]. Following the concept of using the ‘known’ to
discover the ‘unknown’, we thus expanded the subnetwork beyond
the 33 longevity genes to other genes most highly connected to
them, and obtained a larger subnetwork, containing 742 genes
(Table 1, Table S2). By assigning importance to the closeness of
connection with known longevity genes, we were thus able to
suggest several hundred additional genes that may influence the
aging process. One such example, among the top 20 genes for the
closeness of connectivity with the 33 ‘known’ longevity genes
(Table 1), was the eukaryotic translation initiation factor 4E
(eIF4E) binding protein 1 (Eif4ebp1,o r4E-BP1) which, in the
unphosphorylated state, represses mRNA translation by binding to
eIF4E. Since it regulates adipogenesis and metabolism [12], and
one of the mediators of its phosphorylation is insulin signaling
Author Summary
The progression of aging is controlled by both genetic and
environmental factors. Many of these factors are present
also in adipose tissue, which itself has been shown to
determine lifespan. Applying advanced bioinformatics
methods on a large mouse gene expression data set, we
identified Pparg (Nr1c3), an important metabolic controller
that regulates the expression of many other genes
particularly in adipose tissue, to be associated with
longevity. This association was verified in experimental
mouse models where the lowered expression of Pparg
reduced lifespan. In addition to Pparg, our analysis
identified .700 potential novel aging genes in mouse
adipose tissue. More generally, these findings suggest that
lifespan may not be a random process but controlled by a
purposeful genetic program.
Figure 1. A subnetwork of likely longevity genes in mouse adipose tissue. (A) Longevity-related subnetwork of 775 genes, extracted from
the mouse adipose transcriptional network of 13,088 genes. The 33 ‘‘known’’ longevity genes used as a seed set are depicted as green diamonds, and
the 213 genes overlapping from the mouse WAT rosiglitazone signature in blue circles. The 5 gene overlap of ‘‘known’’ longevity genes and
rosiglitazone signature is shown as blue diamonds. Pparg, shown as a red circle, is part of the rosiglitazone signature. (B) The distribution of mean
shortest path lengths (m) for the set of 33 ‘‘known’’ longevity genes and 10
6 randomly selected sets of 33 genes within the mouse consensus network.
Red arrow marks the mean shortest path (m=6.7102) for the ‘‘known’’ longevity genes.
doi:10.1371/journal.pgen.1000752.g001
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signaling on longevity. Moreover, in Drosophila 4E-BP plays an
important role in lifespan extension upon dietary restriction [14].
Eif4ebp1 has furthermore been identified as a ‘‘funnel factor’’ in
cancer, through which several oncogenic pathways converge [15].
Biological pathway enrichment analysis is a powerful tool to uncover
functional associations within an a priori selected set of genes. When
applied to the aging subnetworkof 742 genes (excluding the 33 ‘known’
longevity genes from the full set of 775 genes to eliminate bias),
significant enrichment was revealed in several ontology classes with
established links to aging such as complement and coagulation cascade
(i.e. inflammation), insulin signaling, and ubiquinone pathway (i.e.
oxidative stress) (Table 2). Importantly, however, several pathways
lacking previously demonstrated association with longevity also
appeared among the significantly enriched ontologies. One of these,
the PPAR signaling pathway, was actually ranked the highest for the
enrichment of all potential longevity genes. Although direct in vivo
evidence linking Ppars to aging are scarce, conceptual evidence does
exist [16,17], including links to age-related changes in inflammatory
response, insulin sensitivity, distribution and proportion of body fat,
oxidative stress [18], and fatty acid oxidation rate. Of the three actual
Ppar family members, the only one that was present within the aging
subnetwork was Pparc (Table S2). Given that signaling through Pparc
is also of vital importance to proper adipose tissue development and
function [9,10,19–21], and that Pparc is regulated in WAT by one of
the best established longevity determinants, mammalian SIR2
orthologue sirtuin 1 (Sirt1) [22], we hypothesized that perturbing
Pparc signaling might affect longevity.
We first tested this hypothesis in silico by using the WAT gene
expression signature generated from mice with chemically
modulated Pparc activity through the administration of the Pparc
agonist, rosiglitazone [11]. Notably, 213 out of the 1669 genes
whose transcriptional expression was altered by Pparc activation,
overlapped with the genes in the aging subnetwork at a very high
significance level (p=5.2028*10
230) (Table S2). This finding thus
validates the association of Pparg with the aging subnetwork and
further implicates it as a potential determinant of the aging
phenotype.
To put this hypothesis to further rigorous in vivo testing, we
investigated the role of Pparg in longevity in two mouse models
with genetically altered levels of Pparg expression: the hypomorphic
Pparg1/2 knock-out mouse, which lacks Pparg exclusively in WAT
(Figure S1A) and is severely lipodystrophic and remains insulin
resistant throughout life [19]; and the Pparg2 deficient mouse that
lacks Pparc2 in all tissues (Figure S1B) and shows some features of
moderate lipodystrophy and insulin resistance at a young age [23],
but which fully compensates upon aging (see below). The nearly
complete knockdown of Pparg1 and Pparg2 in the WAT of male
Pparg
hyp/hyp mice resulted in a reduction in lifespan by approxi-
mately 16 weeks when compared to the wild type mice (93.764.4
vs 109.663.4 weeks, p=0.03) (Figure 2A). In some respects this
observation goes against the prediction that reduced fat mass, as
seen during CR [4,5], would increase longevity; however, if the
known insulin sensitizing effects of Pparc were key to mediating
the effects of CR, then one would expect reduced longevity in the
Pparg
hyp/hyp mice, where whole body insulin resistance is promi-
nent. However, one potentially confounding factor in this
experiment is the profound lipodystrophy exhibited by the
Pparg
hyp/hyp mice, which may not represent ‘normal’ metabolic
environment due to the amount of metabolic compensation by the
upregulation of other signaling pathways that these mice need for
survival [19]. Also, although differences in the amount of gross
Table 1. Top 20 genes most highly connected to the set of 33 ‘‘known’’ longevity genes in male mouse adipose tissue.
Gene symbol Rank
a Distance
b Gene name
Hoxa7 1 4.636 homeo box A7
Npr3 2 4.697 natriuretic peptide receptor 3
Tmem182 3 4.697 transmembrane protein 182
Plxnb2 5 4.758 plexin B2
Fads3 6 4.788 fatty acid desaturase 3
Mcam 7 4.788 melanoma cell adhesion molecule
Mmd 8 4.818 monocyte to macrophage differentiation-associated
1110006G14Rik 9 4.818 RIKEN cDNA 1110006G14 gene
Palmd 10 4.848 palmdelphin
Fry 11 4.879 furry homolog (Drosophila)
Apcdd1 12 4.879 adenomatosis polyposis coli down-regulated 1
Gpt1 13 4.909 glutamic pyruvic transaminase 1, soluble
Prelp 14 4.909 proline arginine-rich end leucine-rich repeat
Eif4ebp1 15 4.909 eukaryotic translation initiation factor 4E binding protein 1
MMG00345348 17 4.909 NA
Echdc3 18 4.909 enoyl Coenzyme A hydratase domain containing 3
Fzd4 19 4.970 frizzled homolog 4 (Drosophila)
Apol6 20 4.970 apolipoprotein L, 6
Rtn2 21 4.970 reticulon 2 (Z-band associated protein)
Smoc1 23 4.970 SPARC related modular calcium binding 1
aRank within the whole male mouse adipose tissue network of 10,388 genes.
bDistance to the subnetwork of 33 ‘‘known’’ longevity genes.
doi:10.1371/journal.pgen.1000752.t001
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exclude the possible contribution of more discrete tumors to the
decreasedlongevityofthePparg
hyp/hyp mice.Interestinglythough,the
males of an equally lipodystrophic A-ZIP/F-1 mouse model have
more than 40% mortality rate before 30 weeks of age [8], in
comparison to the Pparg
hyp/hyp mice which survived 85% of the
average ,2 year lifespan of wild type mice. In this sense, Pparg
hyp/hyp
mouse model is one of the longest living severely lipodystrophic
models reported.
In order to assess more directly the effects of Pparg on longevity,
without the added complication of reduced adiposity or insulin
sensitivity, we made use of Pparg2
2/2 mice that we generated in
the laboratory and which lack Pparc2, the WAT enriched Pparc
isoform, in all tissues. Although young Pparg2
2/2 mice are lean
[23], our ,2 year old Pparg2
2/2 mice had the same total and lean
body mass, body fat content (Figure S2A and S2B), and caloric
intake (12.3361.53 vs. 14.2461.53 kcal/day/mouse, p=0.421) as
their age-matched littermate controls. Young Pparg2
2/2 mice have
also been reported to be insulin resistant [23]. Again in contrast,
there were no differences in glucose tolerance, the HOMA index
for insulin resistance, nor in circulating insulin or adiponectin
levels between our Pparg2
2/2 and Pparg2
+/+ mice at ,2 years of
age (Figure S2C, S2D, S2E, S2F). Thus, our aging Pparg2
2/2 mice
represent a very metabolically ‘clean’ model for investigating the
role of Pparg2 in longevity.
Consistent with reduced longevity in the Pparg
hyp/hyp mouse, we
noted a significant decrease in lifespan in Pparg2
2/2 mice. The
female Pparg2
2/2 mice lived, on average, 8.8 weeks less than their
wild type controls (p=0.02 when limiting the analysis to those
living no more than 120 weeks), although this difference seemed to
Table 2. Pathway analysis of the predicted novel longevity genes in male mouse adipose tissue.
Pathway Gene count p Overlap genes
Overlap Pathway
PPAR signaling pathway 11 69 0.00066 Apoa5, Apoc3, Aqp7, Cpt2, Fabp3, Gyk, Pck1, Pparg, Rxrg, Slc27a2, Sorbs1
Ubiquinone biosynthesis 4 9 0.00069 Coq5, MMG00237617, ND5, Ndufa12
Valine, leucine and isoleucine degradation 8 40 0.00078 Acat1, Aldh6a1, Auh, Dld, Echs1, Hibadh, Mccc1, Mcee
Pentose phosphate pathway 6 25 0.00133 Aldob, Fbp1, Fbp2, H6pd, Pgm2, Tkt
Complement and coagulation cascades 10 65 0.00153 C1r, C2, F2, Fgb, Fgg, Hc, Kng1, Plg, Serpine1, Serpinf2
ECM-receptor interaction 11 80 0.00230 Cd44, Col2a1, Col3a1, Col4a1, Col5a3, Fn1, Fndc1, Itga6, Itga7, Spp1, Thbs2
Propanoate metabolism 6 29 0.00300 Acacb, Acat1, Aldh6a1, Echs1, Ldhc, Mcee
Carbon fixation 5 23 0.00536 Aldob, Fbp1, Fbp2, Gpt1, Tkt
Insulin signaling pathway 14 133 0.00760 Acacb, Eif4ebp1, Fasn, Fbp1, Fbp2, Pck1, Pde3b, Pik3r5, Ppargc1a, Ppp1r3b,
Pygb, Slc2a4, Socs2, Sorbs1
Glycolysis/Gluconeogenesis 7 51 0.01434 Aldh1a3, Aldob, Dld, Fbp1, Fbp2, Ldhc, Pgm2
Pyruvate metabolism 6 40 0.01514 Acacb, Acat1, Dld, Ldhc, Pck1, Pcx
Alanine and aspartate metabolism 5 32 0.02206 Adssl1, Asns, Dld, Gpt1, Pcx
Fatty acid biosynthesis 2 6 0.03434 Acacb, Fasn
Cysteine metabolism 3 15 0.03845 Cars2, Cdo1, Ldhc
Citrate cycle (TCA cycle) 4 26 0.04157 Dld, Idh1, Pck1, Pcx
The input set of 197 genes was determined by the overlap of the full set of 742 potentially novel longevity genes and the set of 3835 genes for which functional data
was available in the KEGG repository at the time of analysis. Note that the 33 ‘‘known’’ longevity genes were excluded from the determination of the input set to
remove bias. Only those pathways with p,0.05 are shown.
doi:10.1371/journal.pgen.1000752.t002
Figure 2. Pparg determines longevity. (A) Lifespan of hypomorphic (hyp) Pparg deficient mice (n=38 wild type and 24 Pparc
hyp/hyp mice).
** p=0.003. (B) Lifespan of Pparg2 knock-out mice (n=25 wild type and 26 Pparg2
2/2 mice). * p=0.020 when mice .120 weeks were excluded from
the test.
doi:10.1371/journal.pgen.1000752.g002
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differences that could contribute to mortality were not observed
between the genotype groups, although again the contribution of
more discrete tumors can not be excluded. Since the Pparg2
2/2
mice had reduced longevity, comparable to that in Pparg
hyp/hyp
mice, but were not lipodystrophic or insulin resistant, our
observations point more towards a specific role for Pparc2 and
any of its downstream pathways in the regulation of longevity,
rather than mere changes in fat content and/or insulin signaling.
Together our studies thus reveal another genetic factor, Pparg2,
that affects the basic mechanisms of aging, independent of changes
in fat mass or insulin sensitivity [1,2,7]. Interestingly, a potential
molecular mechanism linking aging and Pparc has recently been
suggested to involve a steroid receptor coactivator-1 (SRC-1) as
the age-induced loss of PPARc/SRC-1 interactions increased the
binding of PPARc to the promoter of a model adipogenic gene for
fatty acid binding protein 4 (FABP4, also called aP2) [24].
Both our in silico and in vivo results in the mouse tie longevity
tightly together with signaling through Pparc, and especially the
Pparc2 isoform. We have recently shown increased longevity in
knock-in mice carrying the Ala12 allele of the common human
genetic variant Pro12Ala variant of PPARG2 [25], which associates
with leanness and improved insulin sensitivity in both man and
mouse [25–27]. The species gap between mice and humans for the
role of Pparc2 in longevity is bridged by the observation that
lifespan is increased also in human carriers of the Ala12 allele of
the Pro12Ala variant of PPARG2 [28]. In the clinical setting,
therefore, the links we show between longevity and both Pparg and
the rosiglitazone signature suggest that thiazolidinediones [29]
(TZDs), like rosiglitazone or pioglitazone which are widely used
Pparc agonists and insulin sensitizers in the treatment of type 2
diabetes mellitus (T2D), could be beneficial for longevity. On the
face of it, this may in fact seem paradoxical, considering that
impaired insulin signaling through insulin receptor or its substrates
increases, rather than decreases lifespan in a number of mouse
models [1,2,7]. However, this can be reconciled by the fact that
these models are primarily protected from the detrimental effects
of age-induced increase in plasma insulin levels as TZDs lower
circulating insulin levels [30,31]. Fittingly, low insulin levels and
maintained insulin sensitivity characterize human centenarians
[32]. In light of the above, the results from ongoing outcome trials
evaluating the long-term health benefits of treatments with
PPARc-agonists, i.e. TZDs, are eagerly awaited.
In summary, we have identified a substantial set of potential
novel longevity genes in mouse adipose tissue, and demonstrate, as
a case study, the significant effects of perturbed Pparc activity on
mouse lifespan. Furthermore, our network analysis suggests that,
at least in the context of adipose tissue, the determination of
longevity may not be a random process, but governed by a
concerted effort of a distinct subnetwork of genetic players.
Materials and Methods
Ethics statement
Animal experiments were approved by the local ethics
committee and performed according to governmental guidelines.
Compilation of the seed set of 60 ‘‘known’’ longevity
genes
To obtain a list of genes with known association to longevity, we
used the Phenotypes section of the Mouse Genome Informatics
(MGI) resource of The Jackson Laboratory (http://www.informatics.
jax.org/) [33], the GenAge Model Organisms pages for mouse within
The Human Ageing Genomic Resources (HAGR) [34], and a
literature search. The list was compiled in October, 2007.
Generation of the transcriptional network for mouse
adipose tissue
Detailed description of these methods is given in Text S1. In
summary, we obtained male adipose tissue gene expression data
from 4 different mouse F2 crosses [35,36] using Agilent
microarrays, and generated a Bayesian network for each cross
by integrating genetic and gene expression data [37–39]. The
combined network, containing 13088 nodes and 22809 edges, was
obtained as the union of all these 4 separate Bayesian networks.
Connectivity of ‘‘known’’ longevity genes within the
adipose transcriptional network
To assess the degree of connectivity of the 33 ‘known’ longevity
genes that were present in the adipose consensus network, mean
shortest paths were computed using Dijkstra’s algorithm [40] for
our set of 33 nodes (=genes) as well as 10
6 randomly selected sets
of 33 nodes. Briefly, the algorithm finds the smallest number of
edges we have to ‘‘walk’’ in order to ‘‘travel’’ from a source node
(=gene) to another node (=gene) of interest within the map/
network. The probability of finding random sets of 33 nodes with
shorter mean paths than with our set was obtained by counting the
number of such eventualities within the randomized sets, and
amounted to a p-value of 0.00149, demonstrating that indeed our
33 genes are much more connected within the adipose tissue
consensus network than expected by change. Kolmogorov-
Smirnov (KS) test was used to further assess whether there were
any significant differences between the shortest path distribution
within our longevity gene-set and those within each of the 10
6
random sets. The resulting p-value distribution demonstrated that
indeed the longevity genes shortest path distribution is not a
normal occurrence in the network.
Generation of Pparg
hyp/hyp and Pparg2
2/2 mice
Pparg2
2/2 mice were generated from Pparg
hyp/hyp [19] mice by
successive matings with transgenic C57Bl/6J mice expressing FLP
and Cre recombinases to remove the Pparg2 specific exon B. All
mice studied were backcrossed a minimum of 9 generations to
achieve an essentially pure C57Bl/6J background.
Survival
The original survival cohorts consisted of 38 wild type and 24
Pparg
hyp/hyp male, and 25 wild type and 26 Pparg2
2/2 female mice
which were maintained on a 12 hour light/dark cycle, fed regular
chow, had free access to H2O and received standard animal care.
The mice were bred locally and were entered into the survival
cohort over the course of 23 weeks for male Pparg
hyp/hyp mice, amd
19 months for female Pparg2
2/2 mice. For all groups, deaths were
recorded weekly. Mice observed as moribund were euthanized
and recorded as dead on that week. All Pparg
hyp/hyp reached the
end-point, but a few Pparg2
2/2 mice survived at the time of
analysis.
Metabolic exploration of Pparg2
2/2 mice
Approximately 2 year old wild type (n=5) and Pparg2
2/2 (n=9)
mice were subjected to the following analysis according to
standardized Eumorphia/EMPReSS (http://empress.har.mrc.ac.
uk/) protocols: body composition by quantitative nuclear magnetic
resonance on a Minispec analyzer (Bruker Optics, The Wood-
lands, TX), food intake, intraperitoneal glucose tolerance test
(IPGTT), and fasting plasma insulin and adiponectin measure-
Pparc2 Determines Longevity
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Uppsala, Sweden) and Quantikine Mouse Adiponectin/Acrp30
Immunoassay (R&D systems Inc., Minneapolis, MN), respectively.
HOMA index for insulin resistance was calculated from fasting
glucose and insulin values [41].
RNA analysis
Pparg1 and Pparg2 gene expression in WAT, BAT, liver and
skeletal muscle of Pparg
hyp/hyp mice was previously reported [19]
and is presented for comparative purposes. For Pparg2
2/2 mice,
total RNA was extracted from WAT, BAT, liver and skeletal
muscle either with RNeasy for Lipid Tissues Mini Kit (Qiagen,
Valencia, CA) or Trizol (Invitrogen, Carlsbad, CA), and reverse
transcribed to cDNA using SuperScript II System (Invitrogen) and
random hexamer primers. Pparc1 and Pparc2 gene expression
was quantified by qRT-PCR using isoform-specific primers and
SYBR Green chemistry on a LightCycler 480 (Roche, Penzberg,
Germany).
Statistical analyses
Statistical methods pertaining to the network and other
associated analysis of gene expression and gene set data were as
detailed above. Kaplan-Meier survival analysis, which allows for
censored cases, was used to analyze the survival data in SPSS
(version 14). Metabolic and molecular data for Pparg
hyp/hyp and
Pparg2
2/2 mice were analyzed using Student’s t-test and are
presented as means 6 s.e.m.
Supporting Information
Figure S1 Pparg1 and Pparg2 gene expression in WAT, BAT,
liver and skeletal muscle in mouse models with altered Pparg locus.
Data are presented relative to mean WAT expression in the wild
type (Pparg
+/+) for each Pparg isoform. Note the much lower
expression levels in liver and muscle. (A) Hypomorphic Pparg
deficient mouse. (B) Pparg2 knock-out mouse. Note that only one
mouse per group was analyzed.
Found at: doi:10.1371/journal.pgen.1000752.s001 (0.07 MB TIF)
Figure S2 Metabolic phenotype of ,2 year old Pparg2 knock-out
mice. For all tests, n=4–9 per group. (A) Unaltered body weight
and (B) fat content were analyzed by QNMR and are presented in
% of fat of total body weight. (C) Intraperitoneal glucose tolerance
test. The mean areas under the curve above baseline (AUC) are
shown in the inset. (D) HOMA index for insulin resistance,
calculated from fasting glucose and insulin values. (E) Fasting
insulin and (F) adiponectin levels. None of the comparisons
showed statistical significance.
Found at: doi:10.1371/journal.pgen.1000752.s002 (0.06 MB TIF)
Table S1 The seed set of 60 ‘‘known’’ longevity genes in mouse
for the identification of a novel transcriptional longevity
subnetwork. The gene list was derived from public resources (see
Materials and Methods). The overlaps with the consensus white
adipose tissue network (33 genes) and the rosiglitazone signature in
the mouse WAT (5 genes) are indicated by a plus sign.
Found at: doi:10.1371/journal.pgen.1000752.s003 (0.03 MB
XLS)
Table S2 Listing of 742 potentially novel longevity genes. Genes
are ranked for the strength of connectivity with the network of the
33 ‘‘known’’ longevity genes within the male mouse adipose tissue
transcriptional network of 13,088 genes.
Found at: doi:10.1371/journal.pgen.1000752.s004 (0.12 MB
XLS)
Text S1 Supporting Methods.
Found at: doi:10.1371/journal.pgen.1000752.s005 (0.18 MB
DOC)
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